NVNO (enVVeno Medical) EBIT: $-20.01 Mil (TTM As of Mar. 2026)


NVNO enVVeno Medical Corp NVNO
26 GF Score
Price $11.37
! 3 Warning Signs
View Full Analysis

What is enVVeno Medical EBIT?

enVVeno Medical NVNO +16.14% 26 EBIT is $-20.01 Mil as of Mar. 2026. GuruFocus rates NVNO with a GF Score™ of 26/100. The stock has 3 warning signs investors should review.

enVVeno Medical's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-4.06 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-20.01 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. enVVeno Medical's annualized ROC % for the quarter that ended in Mar. 2026 was -929.25%. enVVeno Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2,534.79%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. enVVeno Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 119.54%.

enVVeno Medical  (NAS:NVNO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

enVVeno Medical's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-16.248 * ( 1 - 0% )/( (2.055 + 1.442)/ 2 )
=-16.248/1.7485
=-929.25 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=29.562 - 0.803 - ( 28.212 - max(0, 2.122 - 28.826+28.212))
=2.055

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=26.097 - 1.309 - ( 24.93 - max(0, 2.143 - 25.489+24.93))
=1.442

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

enVVeno Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-16.248/( ( (0.705 + max(-1.118, 0)) + (0.577 + max(-1.188, 0)) )/ 2 )
=-16.248/( ( 0.705 + 0.577 )/ 2 )
=-16.248/0.641
=-2,534.79 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.614) - (0.803 + 0 + 0.929)
=-1.118

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.559) - (1.309 + 0 + 0.438)
=-1.188

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

enVVeno Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-20.007/-16.736
=119.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

enVVeno Medical EBIT Related Terms

enVVeno Medical EBIT Historical Data

* Premium members only.

The historical data trend for enVVeno Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

enVVeno Medical EBIT Chart

enVVeno Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.89 -24.93 -25.24 -23.83 -20.90

enVVeno Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.95 -7.05 -4.88 -4.01 -4.06

NVNO vs BMRA, STME, TNON: EBIT Comparison

For the Medical Devices subindustry, enVVeno Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

enVVeno Medical EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, enVVeno Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where enVVeno Medical's EV-to-EBIT falls into.


NVNO
26GF Score
enVVeno Medical Corp NVNO
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

enVVeno Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-20.01 Mil mean?
enVVeno Medical (NVNO) has a EBIT of $-20.01 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on enVVeno Medical.
Is enVVeno Medical's EBIT too high?
enVVeno Medical's current EBIT is $-20.01 Mil. Overall, enVVeno Medical has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does enVVeno Medical's EBIT compare to BMRA and STME?
enVVeno Medical's EBIT of $-20.01 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on enVVeno Medical. enVVeno Medical's current EBIT is $-20.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enVVeno Medical stock overvalued right now?
enVVeno Medical (NVNO) has a current EBIT of $-20.01 Mil. The current EBIT is $-20.01 Mil. enVVeno Medical's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For enVVeno Medical (NVNO), the current EBIT is $-20.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

enVVeno Medical Business Description

Address 70 Doppler, Irvine, CA, USA, 92618
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
26GF Score

Get the complete analysis for NVNO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.37
Price